FDA Approves J&J’s ICOTYDE Oral Peptide for Psoriasis
SPRING HOUSE, Pennsylvania, USA – March 18, 2026 In a major advancement for dermatology and systemic therapies, Johnson &...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
SPRING HOUSE, Pennsylvania, USA – March 18, 2026 In a major advancement for dermatology and systemic therapies, Johnson &...
KANAGAWA, Japan, Dec. 17, 2025 — PeptiDream Inc. announced promising pre-clinical results for a novel oral dual IL-17A and...
